Tardieu S, Micallef J, Bonierbale M, Frauger E, Lançon C, Blin O
Cellule d'Evaluation Médicale, Santé Publique, Assistance Publique-Hôpitaux de Marseille, 80, rue Brochier, 13354 Marseille cedex 05, France.
Encephale. 2006 Oct;32(5 Pt 1):697-704. doi: 10.1016/s0013-7006(06)76221-2.
In spite of the frequency of sexual dysfunction in schizophrenic patients and antipsychotic-treated schizophrenic patients, few studies have been performed. The relationship of schizophrenia to sexual pathology is variable and complex, and of course different between men and women. Few evaluation methods have been proposed or validated. Antipsychotics may improve some aspects of sexual behaviour in schizophrenic patients. However, sexual dysfunction is also a possible side effect of these drugs. The evaluation of antipsychotics is often restricted to prolactin measurement, the relationship with sexual disorders of which has not been fully established. Preliminary data suggest that the capacity to induce sexual disorders differs from one antipsychotic to another. The available data on the mechanisms of sexual dysfunction, the pharmacological profile and the sexual effects of classical neuroleptics (haloperidol and thioridazine) and second generation antipsychotics available in France (amisulpride, clozapine, risperidone, olanzapine) are reviewed.
尽管精神分裂症患者及接受抗精神病药物治疗的精神分裂症患者中性功能障碍很常见,但相关研究却很少。精神分裂症与性病理之间的关系多变且复杂,当然男女之间也存在差异。很少有评估方法被提出或得到验证。抗精神病药物可能会改善精神分裂症患者性行为的某些方面。然而,性功能障碍也是这些药物可能产生的副作用。对抗精神病药物的评估通常局限于催乳素测量,而其与性功能障碍的关系尚未完全明确。初步数据表明,不同抗精神病药物诱发性功能障碍的能力有所不同。本文综述了关于性功能障碍机制、药理特性以及法国现有的经典抗精神病药物(氟哌啶醇和硫利达嗪)和第二代抗精神病药物(氨磺必利、氯氮平、利培酮、奥氮平)的性效应的现有数据。